1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Multiple Sclerosis [2017]

Multiple Sclerosis [2017]

  • November 2017
  • ID: 5251960

Summary

Table of Contents

How will Ocrevus reshape the MS treatment landscape?

A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited about Ocrevus’ approval in relapsing and progressive forms of the disease and Mavenclad’s European approval gives patients another treatment choice, but which therapy will stand out in an evolving and competitive landscape? Other disease modifying therapies are in late-stage development but which segment of the market can they expect to capture? Learn how KOLs see the market evolving, and how they expect developers to differentiate their marketed and pipeline therapies in KOL Insight: Multiple Sclerosis. Twelve of the world’s most prominent KOLs provide their candid insights on ten marketed products and seven Phase III pipeline programmes.

Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!

Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 6 EU & 6 US KOLs are >
• Review an extract from the report - 1 drug profile >

Top takeaways
• How is Ocrevus expected to fare? With approval in RRMS and PPMS, how will this new therapy be prescribed and against which products will it compete?
• Are the new sphingosine modulators set to compete with Gilenya? With ozanimod and ponesimod both undergoing Phase III evaluation, find out how KOLs view these agents.
• Is ofatumumab considered a real threat to Ocrevus or a ‘me-too’ drug? Do KOLs see any potential advantages, or is it too late to the game?
• Where will Mavanclad be positioned in the treatment paradigm? This therapy received EU approval as a treatment for highly active relapsing MS, but how do KOLs envision prescribing it?
• What factors will be important in determining biotin’s (MD-1003) future success'Pharmaceutical-grade biotin is undergoing regulatory review in Europe as a potential therapy for progressive MS, but what will need to be addressed in order to secure commercial success?
• To what extent will oral disease-modifying therapies be prescribed in the future? Find out whether KOLs think these agents’ market share will increase, decrease or stay stable in the near future?
• How are interferon beta products currently being prescribed? Has there been a shift in interferon beta prescribing and how do KOLs envision their use in the future?
• What does the future hold for Copaxone as a therapy for MS? Find out KOLs’ thoughts on how this drug will be prescribed in the future and what impact a thrice-weekly generic is expected to have.

Back to the top
Quotes
“I expect a trial [of ofatumumab] in progressive disease. As a clinical scientist, I would love to see confirmation of the ORATORIO data with a similar or identical approach. I understand that the company is still deliberating on this.”EU Key Opinion Leader
“We are currently using Ocrevus second-line, but in some cases first-line too. We have no barriers to prescribing, not from my standpoint.

Finding infusion chairs is improving. I don’t know that there are any big reimbursement issues, although I think it’s an evolving story.”North American Key Opinion Leader

Sample of therapies covered

Marketed Therapies
• Interferon beta products (Biogen/Merck Serono/EMD Serono/Bayer/Novartis)
• Copaxone (glatiramer acetate; Teva)
• Tecfidera (dimethyl fumarate; Biogen)
• Aubagio (teriflunomide; Sanofi/Genzyme)
• Gilenya (fingolimod; Novartis)
• Tysabri (natalizumab; Biogen)
• Lemtrada (alemtuzumab; Sanofi)
• Zinbryta (daclizumab; Biogen/AbbVie)
• Ocrevus (ocrelizumab; Roche/Biogen)
• Mavenclad (cladribine; Merck Group)

Pipeline Therapies
• ofatumumab (Novartis/Genmab)
• biotin (MD1003; MedDay/Medical Need)
• ozanimod (RPC 1063; Celgene)
• siponimod (BAF 312; Novartis)
• ponesimod (ACT 128800; Actelion)
• ALKS 8700 (Alkermes)
• laquinimod (Nerventra; Active Biotech/Teva)

KOLs interviewed

KOLs from North America
• Prof Mark Freedman, MD, Professor of Medicine in the field of neurology at the University of Ottawa and Director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus, Ottawa, Ontario, Canada.
• Prof Shiv Saidha, MD, MBBCh, Associate Professor of Neurology at Johns Hopkins Medicine, Baltimore, MD, USA.
• Prof David Hafler, MD, William S. and Lois Stiles Edgerly Professor and Chairman of Neurology, Yale School of Medicine and the Neurologist-in-Chief of the Yale-New Haven Hospital, CT, USA.
• Prof Bianca Weinstock-Guttman, MD, Professor of Neurology and Director of the Jacobs Multiple Sclerosis Center for Treatment and Research, University at Buffalo (SUNY), NY, USA.
• Prof Rob Naismith, MD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, MO, USA.
• Prof Aaron Miller, MD, Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis & Professor and Vice-Chair for Education, Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY.

KOLs from Europe
• Prof Patrick Vermersch, MD, Professor of Neurology at Clinique Neurologique, Centre Hospitalier Régional Universitaire de Lille, Centre de Biologie Pathologie Génétique Lille, France.
• Prof Celia Oreja-Guevara, MD, Chair of Clinical Research, Multiple Sclerosis Unit, Department of Neurology, IdISSC, University Hospital San Carlos, Madrid, Spain.
• Prof Óscar Fernández, MD, Professor, Medical Neurologist and Senior Investigator at the Hospital Universitario Virgen de la Victoria, Málaga, Spain.
• Prof Daniel Guillaume, MD, Neurologist and Medical Director of the Centre Neurologique et de Réadaptation Fonctionnelle, Fraiture en Condroz, Belgium.
• Anonymous, German KOL, Professor of Neurology at a leading German university hospital.
• Anonymous, German KOL, Professor of Neurology at a leading German university hospital.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials

Global Central Nervous System Partnering 2012-2018: Deal trends, players and financials

  • $ 3495
  • Industry report
  • October 2018
  • by Currentpartnering

Global Central Nervous System Partnering 2012 to 2018 provides the full collection of Central Nervous System disease deals signed between the world’s pharmaceutical and biotechnology companies since ...

Spasticity - Epidemiology Forecast - 2027

Spasticity - Epidemiology Forecast - 2027

  • $ 3250
  • Industry report
  • October 2018
  • by Delve Insight

DelveInsight’s “Spasticity – Epidemiology Forecast, 2027” report provides an overview of the disease along with global historical and forecasted epidemiological data of Spasticity for the seven ...

Spinal Cord Injury Global Clinical Trials Review, H2, 2018

Clinical Research in Spinal Cord Injury in H2, 2018

  • $ 2500
  • Industry report
  • July 2018
  • by GlobalData

Spinal Cord Injury Global Clinical Trials Review, H2, 2018SummaryGlobalData’s clinical trial report, “Spinal Cord Injury Global Clinical Trials Review, H2, 2018" provides an overview of Spinal Cord ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on